CANY
FATE icon

Caxton Associates (New York)’s Fate Therapeutics FATE Stock Holding History

Caxton Associates (New York)’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-167,957
Closed -$588K – 553
2024
Q3 		$588K Sell
167,957
-4,906
-3% -$19.1K 0.02% 341
2024
Q2 		$567K Sell
172,863
-117,324
-40% -$514K 0.02% 327
2024
Q1 		$2.13M Buy
+290,187
New +$1.8M 0.12% 114
2023
Q3 		– Sell
-40,719
Closed -$194K – 474
2023
Q2 		$194K Sell
40,719
-43,633
-52% -$241K 0.03% 418
2023
Q1 		$481K Buy
+84,352
New +$509K 0.07% 271

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Caxton Associates (New York)'s FATE Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 167,957 shares — an estimated $588K sold.

Caxton Associates (New York) first reported a position in FATE in Q1 2023 and held it in 5 quarters. The position peaked at $2.13M in Q1 2024. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Caxton Associates (New York) reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 167,957 Fate Therapeutics shares in Q4 2024, an estimated $588K.
  • Caxton Associates (New York) first reported a position in Fate Therapeutics in Q1 2023 and held it in 5 quarters.
  • Caxton Associates (New York)'s Fate Therapeutics position peaked at $2.13M in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.